Exploring the mechanism of Tongmai Yangxin pill in treating coronary heart disease by regulating gut microflora based on network pharmacology and molecular docking technology

Numerous studies have confirmed that Tongmai Yangxin pill (TMYXP) is effective in the treatment of coronary heart disease (CHD) with a deficiency of both Qi and Yin in traditional Chinese medicine theory, but whether it works through the regulation of gut microflora (GM) for the treatment of the disease is unclear. The network pharmacology and molecular docking were used to explore the potential mechanism of TMYXP in treating CHD by regulating GM. Based on network pharmacology, the potential target of TMYXP in the treatment of CHD by GM was identified. The network diagram of protein-protein interaction was established to screen the key targets. The biological function and enrichment pathways of TMYXP were analyzed using the DAVID database, and the biological pathway of TMYXP in treating CHD by regulating GM was explored. The key active ingredients and proteins were analyzed through molecular docking simulation. TMYXP may regulate 27 targets and related 34 types of intestinal bacteria to exert cardiovascular protection, with the active substance basis including 145 active ingredients represented by Quercetin and Luteolin. GM plays an important role in the treatment of CHD with TMYXP, whose therapeutic mechanism relates to multi-target and multi-pathway.